Akums Drugs & Pharmaceuticals Ltd

Other Announcement

Akums Drugs & Pharmaceuticals Other Announcement

Akums Drugs and Pharmaceuticals received a voluntary ESG rating of 63 from NSE Sustainability for FY 2024-25. The rating was assigned using publicly available information.

Execution

Financial Year 2024-25

Capacity Expansion

Akums Drugs & Pharmaceuticals Capacity Expansion

Akums Drugs' wholly-owned subsidiary, Pure and Cure Healthcare, executed a lease deed on April 28, 2026, to purchase a 4050 Sq. Mtr industrial plot in Haridwar. Located adjacent to existing facilities, the plot will support business operations.

Credit Rating

Akums Drugs & Pharmaceuticals Credit Rating

Akums Drugs and Pharmaceuticals Limited received credit rating updates from ICRA for Rs. 285 Crore in facilities. ICRA reaffirmed the [ICRA]AA (Stable)/[ICRA]A1+ rating for Rs. 85 Crore in working capital limits and assigned a new [ICRA]A1+ rating to a Rs. 200 Crore commercial paper programme, reflecting a strong liquidity position.

Value

₹285.0 Cr

Other Announcement

Akums Drugs & Pharmaceuticals Other Announcement

Akums Drugs and Pharmaceuticals Limited submitted a compliance certificate for the quarter ended March 31, 2026. The filing confirms the processing of dematerialisation requests by its Registrar and Share Transfer Agent, MUFG Intime India Private Limited, within prescribed timelines.

Financial Results

Akums Drugs & Pharmaceuticals Q3 FY26 Results: Net Profit ₹67.7 Cr, Up 2.1% YoY

Akums Drugs & Pharmaceuticals Ltd reported net profit of ₹67.7 Cr (+2.1% YoY) for Q3 FY26.

Key figure

Net profit ₹67.7 Cr · +2.1% YoY